-
Daiichi Sankyo Receives Negative CHMP Opinion for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AMLDaiichi Sankyo2020-08-03 09:29:33Daiichi Sankyo Receives Negative CHMP Opinion for FLT3 Inhibitor Quizartinib for Treatment of Patients with
-
[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2020-08-03 09:30:09[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with HER2
-
European results from Global ETNA-AF registry show low bleeding and low cardiovascular event rates in elderly NVAF patients on LIXIANA®▼ (edoxaban)Daiichi Sankyo2020-08-03 09:30:42European results from Global ETNA-AF registry show low bleeding and low cardiovascular event rates in elderly
-
The Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid Completes Patient EnrolmentDaiichi Sankyo2019-12-12 16:00:02The Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid Completes Patient Enrolment
-
Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung CancerDaiichi Sankyo2019-12-12 16:00:02Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patients with
-
Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung CancerDaiichi Sankyo2019-12-12 16:00:02Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World
-
Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2 Positive Metastatic Breast CancerDaiichi Sankyo2019-12-12 16:00:02Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2
-
Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA® (edoxaban) in Patients with Atrial FibrillationDaiichi Sankyo2019-12-12 16:00:02Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA® (edoxaban) in Patients with
-
ETNA-AF Registry Data Provide Real-world Evidence of the Efficacy and Safety Profile of LIXIANA® (edoxaban) in Elderly NVAF PatientsDaiichi Sankyo2020-08-03 09:31:20ETNA-AF Registry Data Provide Real-world Evidence of the Efficacy and Safety Profile of LIXIANA® (edoxaban) in
-
Positive Results Highlight Potential of Bempedoic Acid / Ezetimibe Combination for Hypercholesterolaemia with Type 2 DiabetesDaiichi Sankyo2019-12-12 16:00:02Positive Results Highlight Potential of Bempedoic Acid / Ezetimibe Combination for Hypercholesterolaemia with
